INTRODUCTION
Nipah virus (NIPV) was first isolated from cerebrospinal fluid (CSF) specimens collected from encephalitic patients in Malaysia in 1999. Morphologic, serologic and genetic studies indicated that the virus was closely related to Hendra virus (HENV) isolated in 1994 in Australia and both viruses (non-segmented, negativestranded RNA viruses) form the new Henipavirus genus within the Paramyxoviridae family. 1 Its name originated from Sungai Nipah, a village in the Malaysian Peninsula where pig farmers became ill with encephalitis. 2 Nipah virus was first identified as a zoonotic pathogen after an outbreak involving severe respiratory illness in pigs and encephalitic disease in humans in Malaysia and Singapore in 1998 and 1999. Three years later, a genetically distinct NiV independently emerged in India as well as in Bangladesh, where human NiV outbreak events have been reported nearly every year since. A putative NiV also caused an outbreak of disease in horses and people in the Philippines in 2014. To date, there is no reported evidence of NiV outbreaks in humans emerging in any other country than Malaysia, Singapore, Bangladesh, India and Philippines. More than 600 cases of NiV human infections have been reported globally. A total of 276 cases were reported with 106 fatalities (38%) in Malaysia, but case fatalities in later outbreaks in India and Bangladesh were associated with significantly higher case fatality rates of 43 to 100%. 3 From 1998 to 2015, more than 600 cases of Nipah virus human infections were reported. Subsequent outbreaks in India and Bangladesh have occurred with high case fatality.
Virus transmission from bats to humans occurs through inhalation, contact or consumption of NiV contaminated foods. NiV is transmitted by zoonotic (from bats to humans, or from bats to pigs and then to humans) as well as human-to-human routes. Human-to-human transmission is particularly notable in the outbreaks in India and Bangladesh, where it has been reported to account for 75% and 51% of cases, respectively. At present no vaccines or antiviral drugs are available for NiV disease and the treatment is just supportive. Current prevention strategies focus on raising disease awareness in affected areas. 3 Nipah virus can cause a range of mild to severe disease in domestic animals such as pigs. Nipah virus infection in humans causes a range of clinical presentations, from asymptomatic infection (subclinical) to acute respiratory infection and fatal encephalitis. Infected people initially develop influenza-like symptoms of fever, headaches, myalgia (muscle pain), vomiting and sore throat. This can be followed by dizziness, drowsiness, altered consciousness and neurological signs that indicate acute encephalitis. Some people can also experience atypical pneumonia and severe respiratory problems, including acute respiratory distress. Encephalitis and seizures occur in severe cases, progressing to coma within 24 to 48 h. The case fatality rate is estimated at 40% to 75%; however, this rate can vary by outbreak depending on local capabilities for epidemiological surveillance and clinical management. Nipah is believed to be transmitted from what are called flying foxes or mega bats, so called because they are the largest bat species. They eat fruits and live in trees. These are a part of the old-world fruit bat family called pteropid bats. Bats often end up being reservoirs for a number of severe infectious diseases including Ebola, SARS coronavirus, Nipah and Hendra. 5 The persistence and circulation of the virus within the bat population (Pteropus spp.) and the wide geographical range of the potential reservoirs from Madagascar to Australia, have great implications on human and animal public health, prophylaxis and health education measures. 4 
Literature Review
So far only one bibliometric study on international contribution to Nipah virus research during 1999-2010 was conducted by Safahieh, Sanni and Zainab, 6 which examined 462 papers on Nipah virus research, with a focus on identifying active authors, institutions, countries and citations received. Data was extracted from SCI-Expanded database, (Web of Science) and analyzed using descriptive figures and tables. The active contributing countries were USA (with 41.0% share), followed by Australia (19.3%), Malaysia (16.0%), England (6.5%) and France (5.6%). The productive authors are mainly affiliated to the Centre for Disease Control and Prevention, USA and Commonwealth Scientific and Industrial Research Organization (CSIRO) in Australia and University of Malaya Medical Centre, Malaysia.
OBJECTIVES
The present study examines the performance of global Nipah virus research during 1999-2018, based on publications output indexed in Scopus database. The study looks at the distribution of global publication output of the world and of 10 most productive countries, by document type and source type, growth rate of its annual and ten year output, the share of international collaborative publications of leading countries, broad subject-wise publication scatter across sub-fields, identification of significant keywords depicting trends in research, publication output and citation impact of top 15 global organizations and authors, identification of 20 significant journals and characteristics of its 79 high cited publications.
MATERIALS AND METHODS
The publication data on Nipah virus research for the present study was derived from the Scopus database (http://www.scopus.com) covering the period 1999-2018. Keyword "Nipah virus" was searched in "TITLE-ABS-KEY" tag during the period 1999-2018 to get global publication data. This search string was applied first for searching global publication data on Nipah virus research and then further restricted to individual country by name in "country tag" one by one to ascertain publication output of top 10 most productive countries (including India) in Nipah virus research. The first search string was subsequently refined, using analytical tags in Scopus database, by "subject area tag", "country tag", "source title tag", "journal title name" and "affiliation tag", to get data/ information on the distribution of publications output by subject, collaborating countries, author-wise, organization-wise and journal-wise, etc. For citation data, citations to publications were also collected from date of publication till 24 May 2018. The data for the study was collected on 24 May 2018. The data covered for 2018 was incomplete. A number of bibliometric indicators were used to measure the global performance of Nipah virus research. Table 2 ). The top 10 most productive countries in Nipah Virus research accounted for more than 100.0% (113.12%) global publication share and more than 100.0% (148.58%) citation share during 1999-2018. Their ten-early output accounted for more than 100.0% (104.15%) global publication share during 1999-2008 which increased to more than 100.0% (118.81%) during succeeding ten-year period 2009-18. Country-wise, the global publication share of top 10 countries varied widely 4.23% to 45.98% during 1999-2018, with USA accounting for the highest publication share (45.98%), followed by Australia (16.77%), Malaysia (11.09% share) and other 7 countries (from 4.23% to 7.96%) during 1999-2018. The global publication share registered a increasing publication share in USA (8.77%), France (5.16%), Bangladesh (3.63%), India (2.89%), Germany (1.64%), Singapore 
RESULTS

The
International Collaboration
The international collaborative output of top 10 most productive countries in Nipah Virus research as a national share in the country-wise output varied widely from 24.56% to 88.46% with highest share coming from Bangladesh (88.46%), followed by Australia (73.74%), Canada 
Subject-Wise Distribution of Research Output
According to the Scopus classification, the global Nipah virus research output published during 1999-2018 is distributed across seven sub-fields, with medicine accounting for the highest publications share (50.97%), followed by immunology and microbiology (42.51%), biochemistry, genetics and molecular biology (21.25%), agricultural and biological sciences (11.85%), and other 3 sub-fields contribution varying from 4.57% to 6.10% during 1999-2018. Its activity index, which computes change in research activity in the discipline over time [1999] [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] 
